The last eighteen months have been an unprecedented time of unpredictability for the FDA, but moving forward we’re likely going to see an emerging consistency: a higher amount of FDA flexibility on rare diseases. It’s already begun and is likely to accelerate with Prasad and Makary gone. How is this manifesting? FDA flexes flexibility I […]
The post Weekly reads: more FDA flexibility on rare diseases, elephant iPS cells, heritable human CRISPR, RTT rarely used, digit regeneration appeared first on The Niche.